Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

May 25, 2016 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction Form 5 obligations	0287			
Check this box if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section	y 31,			
if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section				
subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Estimated average Section 16. SECURITIES Estimated average Form 4 or Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Estimated average obligations Filed pursuant to Section 16(a) of the Public Utility Holding Company Act of 1935 or Section Section 17(a) of the Public Utility Holding Company Act of 1940	2005			
obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section	0.5			
1(b).				
(Print or Type Responses)				
1. Name and Address of Reporting Person*2. Issuer Name and Ticker or Trading Symbol5. Relationship of Reporting Person(s) to Issuer	Issuer			
BIOCRYST PHARMACEUTICALS INC [BCRX] (Check all applicable)	.S (Check all applicable)			
(Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner (Month/Day/Wear) Officer (give title Other (specify				
4505 EMPEROR BLVD., SUITE 05/23/2016 200				
(Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check				
Filed(Month/Day/Year) Applicable Line)				
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	l I			
1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities 5. Amount of 6. Ownership 7. Nature	of			
Security (Instr. 3)(Month/Day/Year)Execution Date, if anyTransactionAcquired (A) or CodeSecuritiesForm: DirectIndirect(Instr. 3)anyCodeDisposed of (D) (Instr. 8)Beneficially(D) or IndirectBeneficially(Month/Day/Year)(Instr. 8)(Instr. 3, 4 and 5)Owned Following(I)Ownershi Following				
(A) Reported Transaction(s)				
Code V Amount (D) Price (Instr. 3 and 4)				
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.				
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.SEC 1474 (9-02)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)				

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amoun
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	ionDerivative	Expiration Date	Underlying Securiti

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	(Month/Day/Year) f		(Instr. 3 and 4)	
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amou or Numl of Sh
Automatic Stock Option Grant (1)	\$ 3.22	05/23/2016		A	30,000	06/23/2016 <u>(2)</u>	05/23/2026	Common Stock	30,0

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Patel Sanj K 4505 EMPEROR BLVD. SUITE 200 DURHAM, NC 27703	Х					
Signatures						
/s/ Alane P. Barnes, by power of attorney	of 05/25/2016					
**Signature of Reporting Person		Da	te			

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
- (2) Vests 1/12th per month over twelve months beginning June 23, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.